LillyDirect Review

Our assessment

LillyDirect is the manufacturer's own self-pay channel for brand tirzepatide, and the ladder it publishes is genuinely complete: every dose strength, the dispensing pharmacy named, an alternative pharmacy allowed. Three things complicate it. The ladder lives on the brand product's savings page rather than on LillyDirect's own, and only appears once you select a tab. That page distinguishes regular prices from savings-program prices with eligibility conditions. And a month here is twenty-eight days, so a year holds thirteen supplies rather than twelve.

The price is on a page that isn't this seller's

The self-pay ladder is published on the brand product's own savings page, and only once the no-insurance tab is selected. Arrive at LillyDirect's front door and you won't find it there.

The page that would carry LillyDirect's own full self-pay catalog wouldn't open at all. It is unread rather than empty, so nothing here describes what it lists.

Regular prices and savings eligibility

The same block carries a regular-price ladder and a savings-card ladder. They agree at the bottom two rungs and part company above them, with the card quoting a substantially lower figure at the higher strengths and a stated maximum saving attached to each.

The regular price is what you pay without the card, and the card figure sits beside it. Mix the two in a comparison and you are holding a list price against a discounted one.

The two ladders serve different eligibility conditions. Confirm which applies to you before using a discounted figure in your budget.

A month is twenty-eight days, and the page says so

The card defines its own unit in writing, which is unusually honest and changes the arithmetic. A twenty-eight-day cycle produces thirteen supplies in a calendar year, not twelve. One hundred and fifty-seven of the four hundred and twenty sellers here carry at least one figure that is not a monthly rate, and this is one of them.

The headline strength is the starting dose, and the same block states that the starting dose is not approved as a maintenance dose. So the advertised entry figure buys a rung nobody stays on, and the highest listed regular rate is more than double the entry rate.

One presentation is excluded from the headline outright, and the page names which. Three similar products sit behind one number, so check the presentation before you assume the figure covers the pen you want.

Approved product, named pharmacy, no state list

Twenty-five of the four hundred and twenty sellers here publish brand-name prices and no compounded price at all. This is one, and here the manufacturer stands behind the product directly rather than reselling somebody else's figure.

Ninety-four of the four hundred and twenty sellers here name a dispensing or compounding pharmacy. LillyDirect names its own delivery pharmacy and lets you use a pharmacy of your choosing instead. That is a real disclosure on an approved-product route, because the dispensing party is also the party setting the price.

Two hundred and eighty-six of the four hundred and twenty sellers here publish no service area, and this is one of them. What exists instead is a residency condition covering the United States and Puerto Rico, which answers a different question from which states a service reaches.

LillyDirect also states its own structure plainly: the clinicians who see patients are independent service providers, and it says it doesn't influence their prescribing decisions. No individual clinician is named.

A warning letter about this drug line

Eighty of the four hundred and twenty sellers here carry an FDA warning letter. This one, from September 2025, concerns a direct-to-consumer video about the tirzepatide brands. The agency's stated reasoning was that the video grossly misrepresented their safety profile and omitted a contraindication from the boxed warning.

The letter number, its date and the agency's own text are all public. A warning letter is a disclosure, not a finding of guilt, and it is not treated here as a reason to exclude a company or score it down.

Worth knowing: the other manufacturer selling directly to patients carries a letter of the same date, on the same reasoning, about the same video. That says something about how this market advertised in one particular year rather than about either company alone.